Colorectal Cancer Screening, continued

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 184 CE courses, most popular		$109Add to cart
Pick Your Courses
Up to 8 CE hours		$55Add to cart
Individual course$25Add to cart
The page below is a sample from the LabCE course Epigenetics: Diagnostic Methods in the Clinical Laboratory. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Epigenetics: Diagnostic Methods in the Clinical Laboratory (online CE course)
Colorectal Cancer Screening, continued

Cologuard® is a stool DNA-based, noninvasive colorectal cancer screening test. It examines stool for 10 DNA markers as well as hemoglobin using Quantitative Allele-specific Real-time Target and Signal Amplification (QuARTS) technology.
  • Amplifies and quantifies seven gene point mutations and two methylated DNA markers:
    • N-Myc Downstream-Regulated Gene 4
    • Bone Morphogenic Protein 3 (BMP3)
Studies showed that the Cologuard® technology was far more sensitive than fecal immunochemical testing (FIT) at detecting cancer and advanced polyps. Cologuard® had a 13% rate of false positive test results in patients who did not have colorectal cancer or advanced adenomas.27
27. Exact Sciences. "About Cologuard®." Available at: https://www.cologuardhcp.com/about/cologuard-vs-fit.

Cologuard® versus FIT for detection of colorectal cancer. (27)